2 completed, 1 unknown. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Unknown 1 |
| Phase 2 | 1 | Completed 1 |
Follow Adenosine Diphosphate Ribose: new trials by email Literature Review of Adenosine Diphosphate Ribose trials Research Report on Adenosine Diphosphate Ribose
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer Parimparib, Chemotherapy drug, Targeted Therapy Agent - Carcinoma, Non-Small-Cell Lung, EGF-R Positive Non-Small Cell Lung Cancer | Phase 1 | Unknown | Affiliated Hospital of Jiangnan University | 40 | 2022-12-20 | 2024-01-31 |
| Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer Pamiparib, Surufatinib - Ovarian Cancer, Ovarian Carcinoma | Phase 1 / Phase 2 | Completed | Sun Yat-sen University | 29 | 2022-09-22 | 2026-03-10 |
| Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC) Olaparib, Radiation therapy - Breast Neoplasms, Triple-Negative, Breast Neoplasm Malignant Female | Phase 1 | Completed | Institut Curie | 24 | 2017-07-24 | 2025-11-24 |
Carcinoma, Non-Small-Cell Lung (1) · Ovarian Neoplasms (1) · Radiation Injuries (1) · Triple Negative Breast Neoplasms (1)
Affiliated Hospital of Jiangnan University (1) · Institut Curie (1) · Sun Yat-sen University (1)
China (2) · France (1)
2016 (1)